Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity And Upfront Deal Consideration To $132 Million
Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity And Upfront Deal Consideration To $132 Million
09/06/23, 12:09 PM
Location
san diegoIndustry
biotechnology
Round Type
series b
Investors
Samsara Bio Capital, Versant Ventures, Gilead Sciences, Inc., Amplitude Ventures
Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary TentaclesTM platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.
Company Info
Location
10355 science center drive
san diego, california, united states
Additional Info
Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology. On an unprecedented scale, we are leading a fundamental change in the methods of discovery and engineering of multi-specific biologics.